The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial

John G.F. Cleland(University of Glasgow), Theis Lange(Aalborg University), Arantxa González(Instituto de Salud Carlos III), Kenneth McDonald(University College Dublin), Johannes Petutschnigg(German Centre for Cardiovascular Research), Nicolas Girerd(Université de Lorraine), Frank Edelmann(Humboldt-Universität zu Berlin), Burkert Pieske(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Patrick Rossignol(Inserm), Roberto Latini(Mario Negri Institute for Pharmacological Research), Lars Køber(University of Copenhagen), Philippe Rouet(Université Toulouse III - Paul Sabatier), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Pierpaolo Pellicori(University of Glasgow), Jan A. Staessen(Jagiellonian University), Beatrice Mariottoni(Azienda Usl 8 Arezzo), Mamas A. Mamas(University Hospitals of North Midlands NHS Trust), Hans‐Peter Brunner‐La Rocca(Inserm), Mark R. Hazebroek(Maastricht University), Anne Pizard(Inserm), Stéphane Heymans(Maastricht University Medical Centre), Javier Dı́ez(Instituto de Salud Carlos III), Timothy Collier(London School of Hygiene & Tropical Medicine), Stéphanie Grojean(Centre de Médecine Préventive), Fozia Ahmed(Keele University), Dan Atar, Muhammad Javed Khan(Glasgow Royal Infirmary), João Pedro Ferreira(Inserm), Kenneth Dickstein, Andrew L. Clark(University of Hull), Joe Cuthbert(University of Hull), Blerim Mujaj(University Medical Center Freiburg), Franco Cosmi(Inserm), Job A.J. Verdonschot(Maastricht University)
European Heart Journal
September 5, 2020
Cited by 143


Related Papers